Industry Research
-
Outsourcers Who Most Heavily Rely On CDMOs Often Lack CDMO Selection Resources
8/1/2022
The 2022 iteration of ISR’s CDMO Outsourcing Models report relays similarities and differences in how outsourcing decisions are made at drug innovator companies of various sizes.
-
Predicted Changes In Outsourcing Rates For Highly Potent API
8/1/2022
ISR’s latest research on highly potent API manufacturing asks participants whether they expect any change to the proportion of highly potent molecules in their portfolios, as well as any change to their outsourcing rate for high-containment manufacturing.
-
Phase 2/3 Service Provider Attributes Gaining In Selection Importance
7/1/2022
In ISR’s recent CRO Benchmarking study, outsourcers of Phase 2/3 clinical development services were asked to identify attributes that have been rising in importance as CRO selection criteria over the past 12 months.
-
Preferred Provider Agreements For Phase 1 Services
6/1/2022
Forty-two percent of respondents indicated their company has formal agreements in place, but there is a notable difference in preferred provider agreement (PPA) use when viewed through the lens of company size.
-
Outsourcing Differences By Company Size — Biologic Drug Substance Manufacturing
6/1/2022
ISR split the data from its most recent Biologic API CDMO Benchmarking report by large and non-large respondents to highlight the differences in outsourcing preferences and practices.
-
Outsourcers Send A Consistent Message In Phase 2/3 CRO Selection
6/1/2022
Through two online surveys, one focused on the Phase 1 space and another focused on the Phase 2/3 space, recent customers have evaluated the performance of 50 CROs across 20+ attributes.
-
Biologic And Small Molecule Drug Substance CDMO Selection Metrics Align
5/2/2022
ISR’s annual CDMO Benchmarking research asks participants to identify the CDMO attributes that factor into their service provider selection decision.
-
Drug Product CDMO Selection Metrics Point Toward Pandemic-Induced Concern
4/1/2022
ISR’s annual CDMO Benchmarking research asks participants to identify the CDMO attributes that factor into their service-provider selection decisions.
-
Medical Affairs Employee Attributes Critical to Success
3/1/2022
ISR recently interviewed 15 individuals in Medical Affairs departments at Top 50 pharma companies to understand how they view their responsibilities, the challenges they face, and trends they are seeing in the Medical Affairs space.
-
Projected Growth In Commercial Biologics By Therapeutic Area
2/1/2022
In a recent study on the market outlook for commercial bioprocessing, nearly half of respondents currently have marketed biologics to treat autoimmune disorders (47%) and cancer and related conditions (46%).